Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy

We evaluated multiple patient characteristics for their prognostic significance in patients with peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma [AITL; n = 31] and peripheral T-cell lymphoma, not otherwise unspecified [PTCL-NOS; n = 37]). Five-year overall survival (OS) rates in AITL and PTCL-NOS were 49% and 45%, respectively (p = 0.89). Cox proportional hazard model revealed that male sex, hemoglobin <10.0 g/dL and performance status (PS) ≥2 were independently associated with shorter OS in AITL. In patients with PTCL-NOS, low albumin, PS ≥ 2, and mediastinal lymphadenopathy were independently associated with worse OS. When analysis in PTCL-NOS was performed incorporating Prognostic Index for PTCLu (PIT), low albumin and mediastinal lymphadenopathy were still both prognostic for OS. Three-year progression free survival (PFS) rates in AITL and PTCL-NOS were 49% and 47%, respectively (p = 0.578). None of the parameters was significantly associated with shorter PFS in AITL. In patients with PTCL-NOS, PS ≥ 2 and mediastinal lymphadenopathy were independently associated with shorter PFS. The result is in keeping with previous large scale studies. Besides, we showed the potential prognostic importance of albumin and mediastinal lymphadenopathy in patients with PTCL-NOS.

[1]  K. Shitara,et al.  Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results. , 2008 .

[2]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Briones,et al.  Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  P. Gaulard,et al.  Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2008, Blood.

[5]  M. Tan,et al.  Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab , 2008, Leukemia & lymphoma.

[6]  P. Gaulard,et al.  Histologic Evolution of Angioimmunoblastic T-cell Lymphoma in Consecutive Biopsies: Clinical Correlation and Insights Into Natural History and Disease Progression , 2007, The American journal of surgical pathology.

[7]  P. Gaulard,et al.  Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. , 2007, Blood.

[8]  P. Gaulard,et al.  Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. , 2006, Blood.

[9]  T. Barbui,et al.  Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.

[10]  E. Iannitto,et al.  Splenic marginal zone lymphoma: a prognostic model for clinical use. , 2006, Blood.

[11]  Y. Kagami,et al.  Clinicopathologic and Prognostic Significance of Cytotoxic Molecule Expression in Nodal Peripheral T-Cell Lymphoma, Unspecified , 2005, The American journal of surgical pathology.

[12]  K. Karube,et al.  Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis. , 2004, International journal of oncology.

[13]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[14]  Y. Kagami,et al.  Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma , 2003, International journal of hematology.

[15]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[16]  A. López-Guillermo,et al.  Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[18]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[19]  T. Suchi,et al.  A clinicopathologic study of node‐based, low‐grade, peripheral T‐cell lymphoma. Angioimmunoblastic lymphoma, T‐zone lymphoma, and lymphoepithelioid lymphoma , 1991, Cancer.

[20]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[21]  Olker,et al.  A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE , 2000 .